Company profile: Enigma Diagnostics
1.1 - Company Overview
Company description
- Provider of fully automated molecular testing devices for clinics, plus biological products including protein standards (Purified GFP, Plasmodium falciparum, Canine Heartworm Antigen for veterinary diagnostics), the IFI27 gene biomarker to distinguish influenza from bacterial infections, and the Adapter Chimeric Antigen Receptor preclinical NK-92 cell strategy targeting tumor cells in bone metastases.
Products and services
- IFI27: Single-gene biomarker that distinguishes influenza from bacterial infections with high diagnostic accuracy, enabling precise diagnostic classification for clinical decision-making
- Canine Heartworm Antigen: Native-sourced protein standard for veterinary diagnostics that enables detection of heartworm antigen in canine samples during diagnostic workflows
- Purified GFP | AG45-0205-Z: E. coli-derived protein standard exhibiting green fluorescent properties, used in immunology research and laboratory applications requiring fluorescence-based tracking
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Enigma Diagnostics
Transgenomic
HQ: United States
Website
- Description: Provider of nucleic acid purification and analysis products for life sciences research.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Transgenomic company profile →
GenoKey
HQ: Denmark
Website
- Description: Provider of AI-driven combinatorial analytics of genomic and clinical data via the PrecisionLife Innovation Engine to discover novel drug targets, identify drug repositioning candidates, and design diagnostic, prognostic and theranostic clinical decision support tools. Offers precision biopharma and healthcare solutions, including combinatorial risk scores to predict and prevent chronic diseases such as dementia, diabetes and cardiovascular diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GenoKey company profile →
Lexicon Pharmaceuticals
HQ: United States
Website
- Description: Provider of precise medicines for human disease, including INPEFA (sotagliflozin), a once-daily oral tablet that reduces the risk of cardiovascular death, heart failure hospitalization and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. Pipeline includes LX9211 for DPNP (AAK1) and sotagliflozin for type 1 diabetes (US regulatory) and HCM (preclinical).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lexicon Pharmaceuticals company profile →
Quantgene
HQ: United States
Website
- Description: Provider of genomics and AI solutions in cancer diagnostics and liquid biopsy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Quantgene company profile →
Omega Therapeutics
HQ: United States
Website
- Description: Provider of a proprietary epigenomic programming platform (OMEGA Platform) to develop therapeutics by controlling gene expression; conducts the MYCHELANGELO Phase 1/2 trial in non-small cell lung cancer; runs IND-enabling preclinical studies in inflammation/immunology and other diseases to assess gene targets; and offers an expanded access policy for investigational therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Omega Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Enigma Diagnostics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Enigma Diagnostics
2.2 - Growth funds investing in similar companies to Enigma Diagnostics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Enigma Diagnostics
4.2 - Public trading comparable groups for Enigma Diagnostics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →